Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai’s Cancer Strategy Bears Early IO Combo Fruit

Executive Summary

Interim data from a Phase Ib/II of a combination of Eisai’s halichondrin Halaven with Merck & Co’s immuno-oncology product Keytruda suggest it could represent a novel treatment regimen in patients with metastatic triple negative breast cancer, in an early vindication for the Japanese company’s strategy of expanding its oncology franchise.

Advertisement

Related Content

Lenvatinib Measures Up To Sorafenib In HCC But Prospects Limited?
Eisai hopes for Halaven bump with combo
Merck & Co And Eisai Link Up For Combo Cancer Studies

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097856

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel